Nasdaq · Healthcare

Nurix Therapeutics, Inc. (NRIX)

As-reported financials and recent SEC filings for Nurix Therapeutics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$84.0M

Net income

$-264.5M

Net margin

—

Diluted EPS

$-3.05

ROE

-49.1%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$84.0M	$54.5M	$77.0M	$38.6M	$29.8M
Gross profit	—	—	—	—	—
Operating income	$-285.7M	$-213.0M	$-155.1M	$-183.9M	$-117.9M
Net income	$-264.5M	$-193.6M	$-143.9M	$-180.4M	$-117.2M
Diluted EPS	$-3.05	$-2.88	$-2.65	$-3.71	$-2.73

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

1442026-07-02

42026-07-02

1442026-06-25

1442026-06-25

42026-06-25

42026-06-25

8-K2026-06-11

8-K2026-06-08

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on NRIX

Search Nurix Therapeutics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.